AvePoint, Inc. Class A AVPT 深 滬
已收盤 02-06 16:00:00 美东时间
10.57
+0.410
+4.04%
華盛通- 最 高10.665
- 今 開10.39
- 成交量 263.00万股
- 最 低 10.18
- 昨 收 10.16
- 總市值 22.81亿
- 52周最高 20.245
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 10.12
- 委 比 53.46%
- 總股本 2.16亿
- 歷史最高 20.245
- 量 比 0.97
- 振 幅 4.77%
- 歷史最低 3.40
- 每 手 1
- 風險率 2.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
B. Riley Securities Maintains Buy on AvePoint, Lowers Price Target to $22
B. Riley Securities analyst Erik Suppiger maintains AvePoint (NASDAQ:AVPT) with a Buy and lowers the price target from $25 to $22.
02-02 22:48
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Citigroup Maintains Neutral on AvePoint, Lowers Price Target to $15
Citigroup analyst Fatima Boolani maintains AvePoint (NASDAQ:AVPT) with a Neutral and lowers the price target from $16 to $15.
01-14 02:30
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
Stephens & Co. Initiates Coverage On AvePoint with Overweight Rating, Announces Price Target of $18
Stephens & Co. analyst Ren Hefley initiates coverage on AvePoint (NASDAQ:AVPT) with a Overweight rating and announces Price Target of $18.
2025-12-30 22:22
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Evercore ISI Group Maintains Outperform on AvePoint, Lowers Price Target to $18
Evercore ISI Group analyst Kirk Materne maintains AvePoint (NASDAQ:AVPT) with a Outperform and lowers the price target from $22 to $18.
2025-11-07 22:11
AvePoint Expands Channel Strategy with New Azure Data Protection, Global IAMCP Partnership, and Enhanced Marketplace Integrations
AvePoint, a global leader in data security, announces enhanced Azure data protection capabilities within its AvePoint Elements platform. The company also partners with the International Association of Microsoft Channel Partners (IAMCP) to provide innovative solutions and capabilities for partners, while integrating top cloud marketplaces to streamline operations. These efforts aim to strengthen data security, optimize efficiency, and create recur...
2025-10-28 13:00
